Last updated: 2026-09-14 10:43:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Apollomics Inc. (APLM) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $23.25, with a market capitalization of $67.64M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.94 to $42.12. This page covers its latest market performance, valuation, price trends and company information.
$67.64M | |
$23.70 | |
$4,900.00 | |
$3.66 | |
$23.86 | |
5.82K | |
24.95K | |
-- | |
$42.12 | |
$6.94 | |
-- | |
-- |
Apollomics Inc. (APLM) is trading at $24.50 in pre-market trading as of 2026-09-11 23:31:00, up 2.68% ($0.64) from the previous close of $23.86
Pre-market trading shows how investors are pricing APLM before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Apollomics Inc. (APLM) moved from $27.35 to $23.25, representing a decline of 14.98% ($4.10).
The stock traded between $21.21 and $28.29 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 15.72 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 46.4%
APLM is currently trading at $23.25, placing it 46.4% of the way from its 52-week low of $6.94 to its 52-week high of $42.12. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Apollomics Inc. (APLM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.